GenSight’s developing a drug GS030,based on optogenetics, a technology that makes cells responsive to light to treat Retinitis Pigmentosa (RP).
RP is a rare disease that can be occur in isolation or as part of a syndrome.
Some forms of CDG present with RP.
Leave a Reply.
Write something about yourself. No need to be fancy, just an overview.